AngioDynamics Inc., a medical technology company, reported its financial results for the fiscal year ended May 31, 2025. The company experienced a decrease in net sales, reporting $292.5 million, down 3.8% from the previous year. The decline in revenue was attributed to the divestiture of the PICCs, Midline, dialysis, and BioSentry businesses, as well as the discontinuation of the RadioFrequency Ablation and Syntrax product lines, which collectively impacted sales by $33.4 million. Despite the drop in net sales, AngioDynamics recorded a substantial reduction in its net loss, narrowing it by $150.4 million to a loss of $34.0 million. The company's gross margin improved by 300 basis points, reaching 53.9%. Earnings per share reflected a loss of $0.83, a decrease in loss from the previous year's $4.59 per share. The Med Tech segment showed robust performance, with a growth of 19.0%, driven by the success of Auryon and the thrombus management platform. In contrast, the Med Device segment experienced a decline of 16.0%. The company also reported an increase of $18.0 million in cash flow from operations, resulting in a cash usage of $10.1 million. AngioDynamics continues to focus on innovations in R&D and expanding its clinical and regulatory pathways to enhance treatment options in cardiovascular disease and cancer. The company did not provide specific forward-looking guidance in this report.